Refining the Role of Mid-induction Bone Marrow Biopsy in Acute Myeloid Leukemia: A Pilot Study
NCT06323590 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 60
Last updated 2026-05-08
Summary
The purpose of the study is to observe the outcomes of patients with acute myeloid leukemia who do not receive an immediate second round of chemotherapy after undergoing a standard mid-induction bone marrow biopsy.
Conditions
Sponsors & Collaborators
-
University of Alabama at Birmingham
lead OTHER
Principal Investigators
-
Omer Jamy · University of Alabama at Birmingham
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-05-02
- Primary Completion
- 2028-05-31
- Completion
- 2028-05-31
Countries
- United States
Study Locations
More Related Trials
-
S0125, Chemotherapy, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Older Patients With Acute Myeloid Leukemia
NCT00053014 ·Status: TERMINATED ·Phase: PHASE2
-
S0106B Studying Bone Marrow Samples From Women With Acute Myeloid Leukemia
NCT01575535 ·Status: COMPLETED
-
Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors
NCT05035706 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1
-
Clinical Characters and Outcome of Acute Myeloid Leukemia Patients on Correlation to CD200 and CD56 Expression
NCT05512104 ·Status: UNKNOWN
-
Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
NCT00003239 ·Status: COMPLETED ·Phase: PHASE2
-
Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome
NCT03672539 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Diagnostic Study of Gene Alterations in Patients With Acute Myeloid Leukemia
NCT00003931 ·Status: COMPLETED
-
Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults
NCT02535806 ·Status: TERMINATED ·Phase: PHASE2
-
Symptom-Related Cytokines in Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Patients
NCT00504920 ·Status: COMPLETED
-
Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia
NCT00666588 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia
NCT00002549 ·Status: UNKNOWN ·Phase: PHASE3
-
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
NCT04293562 ·Status: RECRUITING ·Phase: PHASE3
-
Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome
NCT01311258 ·Status: RECRUITING
-
TMLI Plus Chemotherapy in High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
NCT06598969 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Biomarkers in Predicting Response to Treatment in Bone Marrow Samples From Young Patients With Acute Myeloid Leukemia
NCT01321385 ·Status: COMPLETED
-
Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT00651261 ·Status: UNKNOWN ·Phase: PHASE3
-
Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Recurrent Acute Leukemia
NCT00002693 ·Status: COMPLETED ·Phase: PHASE1
-
Treatment of Elderly AML Patients With Induction Chemotherapy Followed by G-CSF-Mobilized Stem Cells From Haploidentical Related Donors
NCT02519712 ·Status: TERMINATED ·Phase: NA
-
Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients
NCT01929408 ·Status: COMPLETED
-
Leukemia Stem Cell Detection in Acute Myeloid Leukemia
NCT02927938 ·Status: TERMINATED ·Phase: PHASE3
-
Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Leukemia
NCT02446964 ·Status: COMPLETED ·Phase: PHASE1
-
Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
NCT00061945 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study Evaluating Gemtuzumab Ozogamicin in Acute Myeloid Leukemia
NCT00037596 ·Status: COMPLETED ·Phase: PHASE2
-
Studying DNA in Blood and Bone Marrow Samples From Younger Patients With Acute Myeloid Leukemia
NCT01024127 ·Status: COMPLETED
-
Pilot Evaluation of a Microfluidic Assay to Detect Minimal Residual Disease and Predict Relapse in AML Patients
NCT03488862 ·Status: COMPLETED